Just want to do a write up about one of my favorite characters from my big epic fantasy series I would love to have the spoons to write down someday…….
Carry on.

seen from Singapore
seen from Greece

seen from Brazil
seen from United Kingdom

seen from Germany
seen from United States
seen from United States
seen from Greece
seen from United States
seen from Brazil
seen from Singapore

seen from Australia
seen from China
seen from China
seen from Argentina

seen from Singapore
seen from Malaysia
seen from China
seen from Yemen
seen from United States
Just want to do a write up about one of my favorite characters from my big epic fantasy series I would love to have the spoons to write down someday…….
Carry on.

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Access New Resources for Hosting Externally Led Patient-Focused Drug Development Meetings
by Julien Rashid, Associate
The U.S. Food and Drug Administration (FDA) and patient organizations use patient-focused drug development (PFDD) meetings as a tool to listen to patients and gather their perspectives. During these meetings, patients give their views on living with their conditions and current and future therapies. In 2013, FDA launched the PFDD initiative with plans to host 20 condition-specific meetings, a goal they have since surpassed. In 2015, after two years of demonstrated success, FDA shared the mantle and gave patient organizations the chance to host PFDD meetings (often called “externally led PFDD meetings”). Since then, patient organizations have successfully amplified the voices of patients through nearly 20 additional meetings.
Perhaps you’ve heard about the value of these meetings, or you’re considering or currently planning one. The success of previous meetings may make it look easy, but don’t be mistaken: PFDD meetings are not cut-and-paste. Each event is unique and requires months of planning, but there have been enough meetings that common practices and lessons learned can be shared, and organizations don’t have to start from scratch. For this reason, FasterCures is excited to announce that we are unveiling three new resources based on lessons from the field, specifically designed for those who are interested in hosting externally led PFDD meetings: the PFDD Readiness Assessment, the Smart Practices from Patient Community Leaders planning guide, and the PFDD Community Toolbox.
PFDD leva 81 finalistas universitários aos distritos da Zambézia
PFDD leva 81 finalistas universitários aos distritos da Zambézia
81 jovens membros da Associação dos Estudantes Finalistas e Universitários de Moçambique na Zambézia serão alocados em diversos distritos no presente ano de 2019, o evento enquadra-se da realização da 14ª edição do Projecto Férias de Desenvolvimento do Distrito.
A informação foi avançada nesta sexta feira em Quelimane, pelo Coordenador Províncial da Associação dos Estudantes Finalistas e…
View On WordPress
Estella Lugo, second from rightt, a CMT patient and medical outreach manager for the Hereditary Neuropathy Foundation, an Inspire partner, speaks on “The Voice of the Adult CMT Patient” panel today. “I have fallen 53 times this year so far,” she said, “but I have gotten up 54.” #PFDD #FacesOfCMT https://www.instagram.com/p/BoRyFQBFmVV/?utm_source=ig_tumblr_share&igshid=1ikcai58ng1a5
Your One-Stop Shop to Track Patient-Focused Drug Development Meetings
by Julien Rashid, Associate
Today, we’re unveiling a new resource: our PFDD Meeting Tracker.
In 2012, the U.S. Food and Drug Administration (FDA) launched its Patient-Focused Drug Development (PFDD) initiative. PFDD serves as a venue for patients to inform the FDA’s Center for Drug Evaluation and Research’s (CDER) assessments of benefit-risk for drugs and treatments.
While the FDA has listed every internally led and some externally led PFDD meetings, we saw an opportunity for a complete, collated list of past and future PFDD meetings. If you plan to host a PFDD meeting or if you are just interested in patient-focused drug development, use our tracker to locate resources from past PFDD meetings and to identify future meetings you might want to attend.
You can download a PDF version of our tracker (updated July 6, 2018). It includes all past and upcoming meetings; host organization(s); links to meeting reports, agendas, and video recordings; and information on attendance, public comments, surveys, and consultants. You can also find a more limited version of this tracker online.
On our tracker, you’ll notice there are missing links; those web pages are no longer available. If you have information about an upcoming or past meeting that could be included in this tracker, please contact Julien Rashid. We will be updating it as new information about meetings become available.
Our next blogs on this topic will feature best practices and lessons learned from organizations that have hosted PFDD meetings. Follow us to keep ahead of PFDD news, updates, and resources.
Related Resource:
·Introducing the Externally Led PFDD Blog series: Getting familiar with FDA Resources

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Introducing the Externally-Led PFDD Blog series: Getting familiar with FDA Resources
by Julien Rashid, Associate
“Patient-focused drug development” might sound redundant. Drug development, by default, should be focused on patients, yet, that has not been the reality. In 2012, as part of its commitment to serve the public, the U.S. Food and Drug Administration (FDA) launched its Patient-Focused Drug Development (PFDD) initiative. PFDD is a platform for patients to inform the FDA’s Center for Drug Evaluation and Research’s (CDER) assessments of benefit-risk for drugs.
Through the initiative, the FDA has conducted condition-specific meetings that convene patients, regulators, researchers, developers, and health-care professionals. These meetings differ from typical multi-stakeholder meetings where the patient voice is often diluted. During PFDD meetings, only patients are given the mic.
A Critical Time to Bring the Patient Voice to FDA’s Patient-Focused Drug Development Meeting on Opioid Use Disorder
By Cynthia Grossman, Director, Science of Patient Input
Two years ago, I attended a public meeting on the Food and Drug Administration’s (FDA) Patient-Focused Drug Development (PFDD) for psoriasis. The FDA was interested in gathering the perspectives of patients to understand how they experience the symptoms and daily impacts of psoriasis and their experience with and hopes for treatments.
I found myself sitting near a family whose middle school aged son had been recently diagnosed, and it was difficult not to be struck by the courage he and his parents had to advocate for him and other young people living with psoriasis.
There were a few “aha moments,” not only for the FDA but also for many others in the room during this meeting. The most striking was that psoriasis is much more multi-faceted than many attendees had realized, including the social element of stigma as well as how symptoms such as itching can be extremely distracting and detrimental to patients’ daily lives - even when their psoriasis appears well managed from their clinical presentation.
The R&D system should be measuring and tracking those symptoms that matter most to patients, and the PFDD meetings can be a powerful platform to capture the voice of the patient and make the same information available to all, as many patients are living with multiple conditions.
Having had this experience, I have hope and anticipation about the April 17 PFDD meeting that the FDA is hosting on opioid use disorder.
FDA to focus on autism as part of its Patient-Focused Drug Development program
FDA to focus on autism as part of its Patient-Focused Drug Development program
US – Food and Drug Administration (FDA) released last week a list of conditions that it is planning to assess in the next two years. This will be part of the Patient-Focused Drug Development (PFDD) program. What the PFDD does is that it asks asks patients about their specific disease or condition, how they assess their treatment options that are currently available to them,as well as what their…
View On WordPress